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Abstract 1 
Background 2 
Metabolic syndrome (MetS) is defined by a clustering of cardiovascular (CV) risk factors, and 3 
associates with a heightened inflammatory state. A raised serum high-sensitivity C-reactive protein 4 
(hs-CRP), a marker of inflammation, is also known to associate with CV risk. We have investigated 5 
the relationship between the presence of MetS and serum hs-CRP in a large representative Persian 6 
population cohort without a history of cardiovascular disease (CVD). 7 
Methods 8 
The MASHAD study population cohort consisted of 9,778 subjects, who were recruited from the 9 
city of Mashhad, Iran, between 2007 and 2008. Several CV risk factors were measured in this 10 
population without CVD. Individuals were categorized into quartiles for serum hs-CRP: the 11 
quartiles had median and IQR for serum hs-CRP of 0.72 (0.59-0.85) mg/L, 1.30 (1.14-1.4) mg/L, 12 
2.29 (1.92-2.81) mg/L and 6.63 (4.61-11.95) mg/L respectively. The prevalence of MetS in each 13 
quartile was determined using either International Diabetes Federation (IDF) or Adult 14 
Treatment Panel III (ATPIII) criteria. 15 
Results: 16 
The prevalence of MetS was highest in the 4th quartile for serum hs-CRP [1220 (50.0%)], and 17 
significantly higher than for the 1st quartile (reference group) [634 (25.9%)] (p<0.001).  A positive 18 
smoking habit [OR, 1.47 (1.26-1.70), p<0.001] and the presence of either MetS-IDF [OR, 1.35 19 
(1.18-1.55), p<0.001] or Mets-ATPIII [OR, 1.40 (1.18-1.50), p<0.001] were strong predictors for 20 
being in the 4th quartile for serum hs-CRP. 21 
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Conclusions: 1 
There was a significant association between high levels of serum hs-CRP and the presence of MetS 2 
among individuals without a history of CVD in our Persian cohort.  3 
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Introduction: 1 
      Metabolic syndrome (MetS) is defined by a clustering of several known cardiovascular (CV) 2 
risk factors. 1 These include obesity, dyslipidemia and impaired glucose tolerance, and the 3 
presence of MetS is therefore associated with a high risk of subsequent CV disease (CVD). 2  4 
MetS has a high prevalence 3-5 and is a serious public health concern in Iran. 5 
      High sensitivity C-reactive protein (hs-CRP), is an indicator of a heightened inflammatory 6 
state, and also appears to be a useful biomarker of CVD risk in both Western 6,7 and Iranian 7 
societies. 8,9 There have been strong recommendations to use serum hs-CRP in CVD risk 8 
assessments. 10,11  9 
      The inflammatory state associated with MetS may contribute to the atherosclerotic process 10 
and use of serum hs-CRP in individuals with MetS has been discussed previously. 12  We wished 11 
to determine whether, in individuals without a history of CVD, serum hs-CRP was a discriminant 12 
for the presence of MetS. 13 
Material and Methods: 14 
Subjects 15 
      The study population was recruited between 2007-2008 using a stratified-cluster method and 16 
derived from an ongoing cohort named ‘Mashhad stroke and heart atherosclerosis disorder’ 17 
(MASHAD) study, Mashhad, Iran. The minimum and maximum age of the subjects was 35 and 18 
64 years respectively. The main inclusion criterion for this study was the absence of a past 19 
history of a CV event (unstable angina, myocardial infarction and stroke), heart failure, 20 
peripheral vascular disease including transient ischaemic attack or amaurosis fugax, or a history 21 
of any previous cardiovascular interventions or surgery; however, the presence of traditional 22 
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cardiovascular risk factors including dyslipidaemia, diabetes mellitus and hypertension were not 1 
used as exclusion criteria for the study.  Individuals with any major co-morbidities such as 2 
cancer, autoimmune diseases (eg, systemic lupus erythematous, rheumatoid arthritis, multiple 3 
sclerosis), overt acute or chronic infectious disease, and inflammatory diseases at the time of 4 
recruitment were excluded. Each subject gave informed written consent to participate in the 5 
study, which was approved by the Mashhad University of Medical Science Ethics Committee. 6 
      For all subjects, clinical data were collected from their available records, questionnaires and 7 
face-to-face interview. Anthropometric measurements and standard blood pressure assessment 8 
were performed as previously described. 4 9 
Biochemical analysis  10 
      Plasma and serum were collected following a 12 h fast and stored at -80oC. A fasting blood 11 
glucose (FBG) and full lipid profile were measured using enzymatic methods (Pars Azmun, 12 
Karaj, Iran). Serum hs-CRP concentration was measured by immunoturbidity  (Pars Azmun, 13 
Karaj, Iran).  14 
Metabolic syndrome 15 
      Both the International Diabetes Federation (IDF) and Treatment of High Blood Cholesterol 16 
in Adults (Adult Treatment Panel III [ATP III]) definitions of r MetS were used  in our data 17 
analysis as previously described. 4 IDF-MetS was defined by the presence of three or more of the 18 
following components: fasting plasma glucose ≥6.1 mmol/L; systolic or diastolic blood pressure 19 
≥130 or ≥85 mmHg; High-density lipoprotein cholesterol  (HDL-C) 1.29 mmol/L for women or 20 
1.03 mmol/L for men; triglyceride ≥1.70 mmol/L; and waist circumference ≥80 cm for women 21 
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or ≥94 cm for men. ATPIII-Mets was defined as being present when three of the following 1 
criteria were met: 2 
      Increased waist circumference: >102 cm for men and >90 cm for women; plasma 3 
concentration of HDL-C<  1.03mmol/L for men and 1.29 mmol/L for women; raised values for 4 
plasma triglycerides: 1.70 mmol/L ; systolic or diastolic blood pressure ≥130 or ≥85 mmHg; 5 
FBG ≥110 mg/dL(6.1 mmol/L) 6 
Statistical analysis 7 
      Statistical analysis was performed using SPSS version 23(SPSS Inc., Chicago, IL, USA), 8 
Data were evaluated for normality using the Kolomogorov-Smirnov test.  Student-t tests and 9 
Mann-Whitney tests were used to compare means or medians of variables with or without 10 
normal distribution respectively. Chi-square tests were used to compare the qualitative variables. 11 
Serum hs-CRP concentration distribution was divided into quartiles and patients in the 1st 12 
quartile (lowest level of hs-CRP) were considered as a reference group.  Nominal regression 13 
analysis was used to predict whether serum hs-CRP was related to metabolic and traditional CV 14 
risk factors.  Odds ratios (ORs) with 95% confidence intervals were obtained using regression 15 
analysis. 16 
Results: 17 
      All data were available for the 9778 (of which 3611 [36.9%] were male) participants in this 18 
study,(Table 1). The median and interquartile ranges of hs-CRP in different quartiles were 0.72 19 
(0.59-0.85) mg/L 1st quartile, 1.30 (1.14-1.4) mg/L 2nd quartile, 2.29 (1.92-2.81) mg/L 3rd 20 
quartile and 6.63 (4.61-11.95) mg/L 4th quartile (Table 1).  21 
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      In all our univariate and multivariate analyses, the first quartile served as a reference group. 1 
Subjects in the 4th quartile were significantly older than those in the 1st quartile (49.0±8.3 y 2 
versus 46.9±8.2 y; p<0.0.001, Table 1). Several risk factors, including: blood pressure, lipid 3 
profile, body mass index and waist circumference, history of diabetes mellitus, hypertension, and 4 
current smoking status, showed increased with quartile (Table 1). The percentage of male 5 
participants was significantly lower in the 4th quartile (33.3%) compared to other quartiles, with 6 
the 1st quartile (47.0%) containing the highest % of male subjects (p<0.001).  7 
      The percentage of patients with IDF- MetS in the 1st , 2nd, 3rd and 4th quartiles were 25.9%, 8 
35.0%, 44.7% and 50.0% respectively (p<0.001).  Moreover, based on ATP-III criteria, the 9 
percentage of MetsS in each quartile were found to be 21.0%, 29.5%, 40.5% and 45.9% 10 
respectively (p<0.001). 11 
       Multivariate analysis showed that in all 2nd, 3rd, and 4th quartile groups compared to the 12 
reference group a positive current smoking habit and the MetS were the strongest determinants 13 
for quartile of hs-CRP. In the 4th quartile a positive current smoking habit gave an OR of 1.47 14 
(1.26-1.70) compared to reference group, and for IDF-MetS and ATPIII-Mets the OR were 15 
1.35(1.18-1.55)] and 1.40 (1.18-1.50) respectively (Table 2).  16 
Discussion: 17 
       This was a cross-sectional study with a large sample size of subjects without a history of 18 
CVD. We found a significant worsening of several conventional CV risk factors in the 19 
individuals within the 4th quartile for serum hs-CRP compared to the subjects within the 1st 20 
quartile. The percentage of subjects with MetS within the 4th quartile was approximately two-21 
fold higher than the reference group. This value was slightly greater using the ATPIII definition 22 
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of MetS versus the IDF definition. A high serum hs-CRP in the early phases of atherosclerosis is 1 
considered to reflect vascular inflammation, and its measurement has been advocated as an 2 
adjunct to the assessment of conventional risk factors. 13 The serum hs-CRP concentrations in 3 
asymptomatic individuals, was particularly high in a proportion of individuals; around 25% of 4 
subjects who were in the 4th quartile for serum hs-CRP had serum levels that were greater than 5 
11.95 mg/L.  Several studies with large sample sizes from both the United States and Europe 6 
have demonstrated that serum hs-CRP is useful for the prediction of future CV events among 7 
apparently healthy men and women 10. 8 
      The association between MetS and elevated levels of serum hs-CRP (>3 mg/L) has been 9 
shown in non-diabetic Cuban Americans (55 men and 106 women) aged ≥ 30 years. 14 Serum hs-10 
CRP was also found to be significantly higher in the patients with MetS than in those without 11 
among the diabetic patients. 15 A study of 5,728 subjects with a similar mean age as our study 12 
showed that subjects with three, four, or five features of the MetS, had 5.1, 10.7 and 11.1 times 13 
greater odds of elevated hs-CRP (>3 mg/L) compared to subjects without any features of the 14 
MetS. 16  .  Our results indicate that elevated levels of serum hs-CRP are associated with an 15 
increased prevalence of MetS, which is a cluster of known predisposing risk factors to CV 16 
events. Our results cannot show whether an increased serum hs-CRP is a cause or consequence 17 
of MetS, but highlights the high probability of a concurrent increase in inflammatory status and 18 
MetS. According to in-vitro studies as well as large sample evidence the association between 19 
hyper-inflammation (i.e., defined by increased CRP) and  insulin resistance, adiposity and other 20 
features of MetS is known to be linked to further elevated risk of cardiovascular events. 17 21 
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       The cut off values of serum hs-CRP for Mets in our population differed with definition 1 
of the MetS and was 1.60 mg/L (IDF-defined sensitivity: 66.3%; specificity: 54.7%) and 2 
1.61 mg/L (ATPIII-defined sensitivity: 67.4%; specificity 53.8%). Due to the wide range of 3 
variability of hs-CRP, even in an asymptomatic population, the specificity and sensitivity of 4 
the cut off points are relatively weak.          5 
       Overall, the American Heart Association/Centres for Disease Control recognized that 6 
individuals with a hs-CRP> 3g/L are a high-risk group for CVD. 18 Among our sample 7 
population, 29.2% of subjects were found to have hs-CRP>3 mg/L. It has been reported that 25% 8 
of the middle-aged population in the United States has serum levels of CRP> 3 mg/L; 19 this was 9 
approximately 18% in a Chinese population. 20 It therefore appears that the percentage of 10 
patients with levels of hs-CRP above the threshold for increased risk of CVD, is high in the 11 
Persian population.  12 
      We found that women in our population sample had higher levels of serum hs-CRP than the 13 
men, and this is consistent with previous publications21,22 . The percentage of women increased 14 
in each quartile for serum hs-CRP, with the 4th quartile containing approximately 80% females. . 15 
Whether there is a gender-specific effect of hs-CRP as a risk predictor of CVDs is still subject of 16 
debate, although some studies have reported that serum hs-CRP appeared to be considerably 17 
stronger marker of CV risk in women compared to men. 23 A strong relationship between serum 18 
hs-CRP and development of coronary spasm (an ischaemia-related phenomenon, 19 
angiographically-defined as a >70% methylergonovine-induced coronary artery spasm reduction 20 
in luminal diameter) was found predominantly in women. 24 21 
11 
 
      We found an independent effect of smoking on serum hs-CRP concentrations. The 1 
prevalence of current smokers was significantly higher in the 4th quartile of hs-CRP. While 2 
results of previous studies  have been conflicting, smoking habit appears to be associated with 3 
increased serum hs-CRP.25,26.  4 
      In conclusion we found a significant relationship between serum hs-CRP and the presence of 5 
MetS and current smoking habit in a large Iranian cohort of subjects without a baseline history of 6 
CVD. In this population serum hs-CRP was particularly high in women. As the MASHAD study 7 
is a prospective,  longitudinal cohort there will be opportunity   to quantify the predictive of 8 
value of baseline  hs-CRP concentration on cardiovascular outcome.  9 
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Table 1. Demographic and biochemical characteristics of individuals in quartiles of hs-CRP 3 
       Values expressed as mean ± SD for variables with normal distribution, and median and 4 
interquartile rang for non-normally distributed data. HDL-C, high density lipoprotein cholesterol; 5 
LDL-C, low density lipoprotein cholesterol. *p<0.01, **p<0.05,***p<0.001 6 
 7 
 8 
 9 
 10 
 11 
 1st quartile 
(N=2446) 
0.72 (0.59-0.85)  
mg/l 
2nd quartile 
(N=2463) 
1.30 (1.14-1.4) 
mg/l 
3rd quartile 
(N=2427) 
2.29 (1.92-2.81) 
mg/l 
4th quartile 
(N=2442) 
6.63 (4.61-11.95) 
mg/l 
Age(y) 46.9±8.2 47.6±8.2 48.7±8.1 49.0±8.3*** 
Gender (male) (%) 1149 (47.0%) 1058 (43.0%) 890 (36.7%) 814 (33.3%)*** 
Systolic blood pressure 
(mmHg) 
118.6±18.6 121.1±17.8 122.8±18.5 124.9±20.9*** 
Diastolic blood pressure 
(mmHg) 
77.5±12.0 78.9±12.3 79.9±11.1 80.4±11.5*** 
Fasting blood glucose ( 
mmol/L ) 
4.7±1.6 5.0±1.9 5.3±2.2 5.7±2.7*** 
Total cholesterol ( mmol/L ) 4.7±0.9 4.9±1.0 5.1±1.1 5.2±1.2*** 
Triglyceride ( mmol/L ) 1.2 (0.8) 1.3(0.9) 1.4 (1.0) 1.5(0.9)*** 
LDL-C ( mmol/L ) 2.8±0.8 2.9±0.9 3.1±1.0 3.2±1.0*** 
HDL-C ( mmol/L ) 1.0±0.3 1.1±0.3 1.1±0.2 1.1±0.3*** 
Body mass index (kg/m2) 26.0±4.1 27.2±4.3 28.7±4.4 29.8±5.2*** 
Waist Circumference (cm) 90.7±10.9 94.7±11.1 96.9±11.7 98.6±12.8*** 
Diabetes mellitus (%) 204 (8.4%) 285 (11.7%) 385 (16.1%) 500 (20.9%)*** 
Hypertension (%) 558(23.0%) 724 (29.8%) 837(35.0%) 932 (38.8%)*** 
Current smoking (%) 475 (19.4%) 544 (22.1%) 534 (22.0%) 545 (22.3%)** 
Metabolic syndrome -
IDF(%) 
634 (25.9%) 862 (35%) 1085 (44.7%) 1220 (50.0%)*** 
Metabolic syndrome-ATP III 506(21.0%) 721(29.5%) 975(40.5%) 1115(45.9%)*** 
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Table 2. The relative risk of being within 2nd , 3rd and 4th quartile of hs-CRP associated 6 
with risk factors and metabolic syndrome 7 
 Reference group and 
second quartile 
Reference group and 
third quartile 
Reference group and 
forth quartile 
Age (y) 1.002 (0.99-1.01) 1.02 (1.01-1.03)*** 1.02 (1.01-1.03)*** 
Sex (male) 0.99 (0.87-1.13) 0.86 (0.76-0.97)* 0.85 (0.75-0.96)** 
BMI (kg/m2) 1.06 (1.04-1.07)*** 1.13 (1.11-1.14)*** 1.18 (1.16-1.20)*** 
LDL(mmol/L) 0.996 (0.993-1.00)* 0.99 (0.98-1.00)*** 0.99 (0.98-1.00)*** 
Total cholesterol 
(mmol/L) 
1.01 (1.00-1.01)*** 1.01 (1.01-1.02)*** 1.02 (1.01-1.03)*** 
Current smoking 1.29 (1.22-1.49)*** 1.40 (1.21-1.62)*** 1.47 (1.26-1.70)*** 
Metabolic syndrome-
IDF 
1.18 (1.03-1.35)* 1.32 (1.15-1.51)*** 1.35 (1.18-1.55)*** 
Metabolic syndrome-
ATP III  
1.20 (1.05-1.35)* 1.35 (1.17-1.51)*** 1.40 (1.18-1.50)*** 
Adjusted odds ratios with 95% confidence intervals (95% CI) obtained from multiple logistic 8 
regression tests. BMI, body mass index; *p<0.01, **p<0.05; ***p<0.001 9 
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